Skip to main content
PMC home page
Oncotarget logoLink to Oncotarget
. 2016 Sep 1;7(40):66087–66099. doi: 10.18632/oncotarget.11807

Circadian clock components RORα and Bmal1 mediate the anti-proliferative effect of MLN4924 in osteosarcoma cells

Shuju Zhang 1, Jiaming Zhang 1, Zhiyuan Deng 2, Huadie Liu 1, Wei Mao 1, Fang Jiang 1, Zanxian Xia 1, Jia-Da Li 1
PMCID: PMC5323217  PMID: 27602774

Abstract

The anticancer small molecule MLN4924, a Nedd8-activating enzyme (NAE) inhibitor, triggers cell-cycle arrest, apoptosis, and senescence in cancer cells. In this study, we demonstrate that MLN4924 suppresses osteosarcoma cell proliferation by inducing G2/M cell cycle arrest and apoptosis. Our results indicate that MLN4924 stabilizes the retinoid orphan nuclear receptor alpha (RORα) by decreasing its ubiquitination. RNA interference of RORα attenuates the anti-proliferative effect of MLN4924 in U2OS osteosarcoma cells. MLN4924 up-regulates the expression of p21 and Bmal1, two transcriptional targets of RORα. However, p21 plays a minimal role in the anti-proliferative effect of MLN4924 in U2OS osteosarcoma cells. In contrast, Bmal1 suppression by siRNA attenuates the anti-proliferative effect of MLN4924 in U2OS osteosarcoma cells, indicating that the MLN4924-mediated cell growth inhibition is mediated by Bmal1. These results show MLN4924 to be a promising therapeutic agent for the treatment of osteosarcoma and suggest that MLN4924-induced tumor growth inhibition is mediated by the circadian clock components RORα and Bmal1.

Keywords: MLN4924, osteosarcoma, RORα, Bmal1, neddylation

INTRODUCTION

Osteosarcoma is the most common primary malignant bone tumor in children and adolescents. In the past four decades, osteosarcoma has been treated with neoadjuvant chemotherapy followed by surgical removal of the primary tumor, often followed by additional adjuvant chemotherapy after the surgery. Cis-platinum, doxorubicin, methotrexate and cyclophosphamide have been used most often to treat osteosarcoma. Nevertheless, the 5-year overall survival rate of osteosarcoma is one of the lowest in the pediatric cancers, i.e. ∼65% for localized tumor [1, 2]. It is therefore necessary and urgent to identify new therapeutic strategies for osteosarcoma patients.

Nedd8 is a ubiquitin-like molecule of ∼8 kDa that is covalently linked to a number of proteins by a process known as neddylation. The most well characterized substrates of Nedd8 are the cullin proteins, the scaffold components of Cullin-Ring E3-ubiquitin Ligases (CRLs) that are responsible for ubiquitination of ∼20% of cellular proteins degraded through the ubiquitin-proteasome system [3]. MLN4924 (pevonedistat), a selective Nedd8 activating enzyme (NAE) inhibitor, is an anti-cancer drug currently in clinical trials [4, 5]. Treatment with MLN4924 can suppress the progression of a variety of tumors [6–14]. Various CRLs substrates have been proposed to mediate the anti-cancer effects of MLN4924 [5, 15–17].

In this study, we show that MLN4924 suppresses the proliferation of osteosarcoma cells, which may be mediated, at least partly, through the retinoid orphan nuclear receptor alpha (RORα).

RESULTS

MLN4924 suppresses growth and tumorigenicity of osteosarcoma cells

We first evaluated the effect of MLN4924 on cell proliferation in three osteosarcoma cell lines: MG63, Saos-2 and U2OS. As shown in Figure 1A-1C, one day of MLN4924 (3 μM) treatment did not significantly change the cell growth; however, MLN4924 significantly inhibited the cell proliferation after two days treatment and thereafter. In U2OS cells, MLN4924 suppressed cell growth in a dose-dependent manner (Figure 1D).

Figure 1. MLN4924 inhibits cell growth and tumorigenicity of osteosarcoma cells.

Figure 1

Open in a new tab

A-C. Three osteosarcoma cell lines: MG63, Saos-2 and U2OS were treated with MLN4924 (3 μM) or DMSO. Cell viability was assessed by an MTT assay. Each value is the mean ± SEM of three replicates from a single assay. D. U2OS cells were treated with various concentrations of MLN4924 for 48 h. Cell viability was assessed by MTT assay. E. MLN4924 significantly inhibited the growth of MG63 cells xenografts in vivo. 1 × 106 MG63 cells were injected subcutaneously into the flanks of nude mice. Ten days later, mice were treated with vehicle (control) or MLN4924 (30 mg/kg i.p.) twice a day for 3 days, and then 2 days without treatment for 15 days. F. Tumor weights after 15 days of treatment. *P < 0.05, unpaired t test.

We next determined the anti-tumor activity of MLN4924 in osteosarcoma cells in vivo. MLN4924 was administered to nude mice bearing MG63 xenografts; the tumors were weighted after 15 days of the treatment. As shown in Figure 1E and 1F, MLN4924 significantly decreased the growth of MG63 xenograft tumors.

To determine how MLN4924 affects the cell cycle, a flow cytometry analysis was performed in three osteosarcoma cell lines: MG63, Saos-2 and U2OS in the presence of MLN4924. As shown in Figure 2, after 24 h treatment with MLN4924 (1 μM), cells began to accumulate in G2/M phase. At 48 h after MLN4924 treatment, the cells with more than 4 chromosomes (≥ 4 N DNA content) were significantly increased; this was similar to the MLN4924 effect in HCT116 cells [5].

Figure 2. MLN4924 causes G2/M cell cycle arrest in osteosarcoma cells.

Figure 2

Open in a new tab

Three osteosarcoma cell lines: MG63 A., Saos-2 B. and U2OS C. were treated with DMSO or MLN4924 (1 μM) for 24 and 48 h. Cells were harvested and fixed in ice-cold 70% ethanol overnight at −20°C, and then stained with PI (5 μg/100 μL) for 30 min at 4 °C in the dark. DNA profiles were analyzed by flow cytometry. > 4N cells were shown in D-F. Each value was the mean ± SEM of three replicates from a single assay.

We also investigated the apoptotic effect of MLN4924 in the osteosarcoma cell lines. After labelling with Annexin V-FITC/PI, a flow cytometry was performed to analyze the apoptotic cells. As shown in Figure 3, treatment with MLN4924 (1 μM) for 48 h induced significant apoptosis in MG63 and Saos-2 cells, but not in U2OS cells. (Apoptotic cells: MG63, DMSO: 5.37% ± 0.29, MLN4924: 33.60% ± 4.90, P = 0.003; Saos-2, DMSO: 5.08% ± 0.89, MLN4924: 37.89% ± 2.07, P = 0.004; U2OS, DMSO: 5.60% ±1.81, MLN4924: 6.10% ± 1.25, P = 0.84, Figure 3D)

Figure 3. MLN4924 induces apoptosis in MG63 and Saos-2, but not U2OS cells.

Figure 3

Open in a new tab

A-C. Three osteosarcoma cell lines MG63 (A), Saos-2 (B) and U2OS (C) were treated with DMSO or MLN4924 (1 μM) for 48 h. Cells were harvested and stained with Annexin V-FITC and PI for 20 min in the dark. Apoptosis was analyzed by flow cytometry. D. The graph illustrates the percentage of total apoptosis cells. Each value was the mean ± SEM of three replicates from a single assay. Q1: live cells (annexin V−/PI−), Q2: early apoptotic cells (annexin V+/PI−), Q3: late apoptotic cells (annexin V+/PI+) and Q4:necrotic cells (annexin V−/PI+).*P < 0.05, **P < 0.01 unpaired t test.

MLN4924 increases stability of RORα

The retinoid orphan nuclear receptor alpha (RORα) is an orphan nuclear receptor that regulates gene expression by binding to the ROR response elements (RORE). Recent studies indicate that RORα functions as a tumor suppressive molecule [18]. Interestingly, RORα is degraded by the DCAF1/DDB1/CUL4 E3 ubiquitin ligase complex [19, 20], which might be inhibited by MLN4924. We have therefore reasoned that RORα may mediate the effect of MLN4924.

To investigate whether MLN4924 affects the degradation of RORα, we first examined the endogenous RORα protein levels in osteosarcoma cells treated 24 h with MLN4924. As shown in Figure 4A-4C, RORα was significantly up-regulated in osteosarcoma MG63, Saos-2, and U2OS cells after MLN4924 (1 μM) treatment.

Figure 4. MLN4924 increases the stability of RORα.

Figure 4

Open in a new tab

A-C. The endogenous RORα protein levels detected with Western blot after treatment with MLN4924 (1 μM) or DMSO in MG63 (A), Saos-2 (B) and U2OS (C) cells for 24 h. D. MLN4924 increased the half-life of RORα. U2OS cells were transiently transfected with plasmids expressing the Flag-RORα. At 24 h after transfection, MLN4924 (1 μM) or DMSO were added into respective cell culture media. 24 h later, cells were treated with cycloheximide (CHX) for 0, 3, 6, 4, 9 and 12 h. Equal amounts of whole cell lysates were analyzed by Western blot with a Flag antibody (M2). Actin was used as an internal control. E. The graph illustrates the quantification of RORα by densitometry of triplicate experiments (mean ± SEM). *P < 0.05, **P < 0.01 by post hoc Bonferroni t test. F. MLN4924 decreased the ubiquitination of RORα. Flag-RORα and HA-Ub expression plasmids were transiently transfected into U2OS cells. At 24 h after transfection, MLN4924 (1 μM) or DMSO were added into respective cell culture media. 24 h later, cells were treated with MG132 for 8 h. Equal amounts of whole cell lysates were used for immunoprecipitation (IP). The protein immunoprecipitated by Flag antibody was analyzed by Western blot with HA or Flag antibody. G. The graph illustrates the quantification of ubiquitinated RORα by densitometry of triplicate experiments (mean ± SEM). **P < 0.01 by unpaired t test.

To further investigate if MLN4924 affects the stability of RORα, U2OS cells transiently expressing Flag-labelled RORα (Flag-RORα) were treated 24 h with MLN4924 (1 μM) or DMSO. 48 hours after transfection, cells were incubated 0, 3, 6, 9, and 12 h with cycloheximide (CHX) to inhibit new protein synthesis, and RORα protein levels were analyzed. As shown in Figure 4D and 4E, MLN4924 significantly prolonged the half life of RORα. Without MLN4924, the half life of RORα was about 7 h, whereas only about 20% of RORα was degraded after 12 h in the presence of MLN4924.

Next, we studied the effect of MLN4924 on the ubiquitination of RORα. U2OS cells co-expressing Flag-RORα and HA-tagged uniquitin (HA-Ub) were treated with MLN4924 (1 μM) or DMSO at 24 h after transfection. Cells were incubated 8 h with proteasome inhibitor MG-132 (10 μM) 48 h after transfection, and immunoprecipitation was performed. The anti-Flag antibody was used to pulldown Flag-RORα proteins, and ubiqutination was detected with the anti-HA antibody. As shown in Figure 4F and 4G, the ubiquitination of RORα was decreased by about 70% in the presence of MLN4924.

Suppression of ROR α attenuates MLN4924-induced cell cycle arrest

To determine whether MLN4924 acts through RORα to suppress cell growth, U2OS osteosarcoma cells were transfected with two distinct RORα-specific siRNAs (Figure 5A). The cells were treated 48 and 72 h with MLN4924 (3 μM) or DMSO at 48 h after transfection, and the cell proliferation was monitored with an MTT assay. Compared with cells transfected with a negative control siRNA, MLN4924 was significantly less effective in suppressing the growth of RORα-depleted cells (Cell viability: 48 h, Control: 76.74% ± 1.72, RORα-siRNA-1: 92.62% ± 0.76, P < 0.0001, RORα-siRNA-2: 100.0% ± 1.69, P < 0.0001; 72 h, Control: 67.08% ± 0.80, RORα-siRNA-1: 83.12% ± 1.39, P < 0.0001, RORα-siRNA-2: 79.47% ± 1.97, P < 0.0002, Figure 5B).

Figure 5. Down-regulation of RORα attenuates MLN4924-induced cell growth suppression.

Figure 5

Open in a new tab

A. U2OS osteosarcoma cells were transfected with two distinct RORα-specific siRNAs or a negative control siRNA. 72 h after transfection, whole cell lysates were analyzed with Western blot using an antibody against RORα. B. U2OS cells were treated with MLN4924 (3 μM) or DMSO for 48 h after transfection with RORα-specific siRNAs or negative control siRNA, and the cell proliferation was monitored with an MTT assay at 48 and 72 h after MLN4924 treatment. Each value is the mean ± SEM of three replicates from a single assay (**P < 0.01 by post hoc Bonferroni t test). C. U2OS cells transfected with RORα-specific siRNA or negative control siRNA after MLN4924 (1 μM) treatment for 0, 24 and 48 h. Cells were harvested and fixed in ice-cold 70% ethanol overnight at −20°C, then stained with PI (5 μg/100 μL) for 30 min at 4 °C in the dark. DNA profiles were analyzed by flow cytometry. D. The graph illustrates the percentage of > 4N cell of four replicates from a single assay (**P < 0.01 by post hoc Bonferroni t test).

To further examine whether RORα participated in MLN4924-induced cell cycle arrest, flow cytometry analysis was performed on U2OS cells transfected with control or RORα-specific siRNA-1 after MLN4924 (1 μM) treatment for 0, 24 and 48 h. As shown in Figure 5C-5D, RORα suppression significantly attenuated the G2/M cell cycle arrest after 48h treatment, as illustrated with percentage of cells at > 4N stages (24 h, Control: 10.91% ± 1.50, RORα-siRNA: 5.61% ± 0.18, P = 0.33; 48 h, Control: 53.47% ± 0.80, RORα-siRNA: 31.95% ± 2.95, P = 0.02).

p21 minimally affects the MLN4924-induced cell growth suppression

Next, we investigated the downstream molecules of RORα involved in the MLN4924 anti-cancer effect. RORα is a putative transcription factor for cyclin-dependent kinase (CDK) inhibitor p21WAF1/CIP1. Indeed, RNAi of RORα resulted in downregulation of p21 (Figure 6A). In addition, p21 was up-regulated in osteosarcoma cells MG63, Saos-2, and U2OS after MLN4924 (1 μM) treatment (Figure 6B-6D).

Figure 6. p21 minimally affects the MLN4924-induced cell growth inhibition.

Figure 6

Open in a new tab

A. U2OS osteosarcoma cells were transfected with two distinct RORα-specific siRNAs or a negative control siRNA. 72 h after transfection, whole cell lysates were analyzed with Western blot using antibodies for RORα, p21, Bmal1 and actin, respectively. B-D. The endogenous p21 protein levels detected with Western blot after treatment with MLN4924 (1 μM) or DMSO in MG63 (B), Saos-2 (C) and U2OS (D) cells for 24 h. E. U2OS osteosarcoma cells were transfected with two distinct p21-specific siRNAs or a negative control siRNA. 72 h after transfection, whole cell lysates were analyzed with Western blot using an antibody against p21. F. U2OS cells were treated with MLN4924 (3 μM) or DMSO from 48 h after transfection with p21-specific siRNA or negative control siRNA, and the cell proliferation was monitored with an MTT assay at 48 and 72 h after MLN4924 treatment. Each value is the mean ± SEM of three replicates from a single assay. G. U2OS cells transfected with p21-specific siRNA or negative control siRNA after MLN4924 (1 μM) treatment for 0, 24 and 48 h. Cells were harvested and fixed in ice-cold 70% ethanol overnight at −20°C, then stained with PI (5 μg/100 μL) for 30 min at 4 °C in the dark. DNA profiles were analyzed by flow cytometry. (D) The graph illustrates the percentage of > 4N cell of four replicates from a single assay (*P < 0.05 by post hoc Bonferroni t test).

To determine whether p21 is involved in the MLN4924-induced cell growth suppression, U2OS cells were transfected with two distinct p21-specific siRNAs (Figure 6E). Although both siRNAs significantly decreased the p21 levels, no significant effect was observed on the cell growth suppression elicited by MLN4924 (3 μM) (Cell viability: 48 h, Control: 63.32% ± 2.41, p21-siRNA-1: 57.68% ± 1.74, P = 0.071, p21-siRNA-2: 58.80% ± 1.34, P = 0.11; 72 h, Control: 47.60% ± 0.89, p21-siRNA-1: 47.10% ± 0.82, P = 0.68, p21-siRNA-2: 44.35% ± 1.59, P = 0.08, Figure 6F).

Then, we performed flow cytometry analysis of U2OS cells transfected with control or p21-specific siRNA-1 after MLN4924 (1 μM) treatment for 0, 24 and 48 h. As shown in Figure 6G and H, p21 suppression had a minimal effect on the MLN4924-induced G2/M accumulation and increase in the > 4N cells (24 h, Control: 25.01% ± 1.29, p21-siRNA: 16.87% ± 1.65, P = 0.06; 48 h, Control: 61.84% ± 1.71, p21-siRNA: 54.16% ± 0.25, P = 0.05).

MLN4924 increases Bmal1 expression at the transcriptional level

RORα induces the expression of Bmal1, the essential component of circadian clock. As expected, RNAi of RORα resulted in downregulation of Bmal1 in the absence or presence of MLN4924 (Figure 6A and Supplementary Figure S1). Recently, Bmal1 has been demonstrated to suppress cell growth through G2/M cell cycle arrest [21–24], suggesting that Bmal1 functions downstream of the MLN4924-RORα pathway.

To investigate the role of Bmal1 in the anti-cancer effect of MLN4924, we first examined the endogenous Bmal1 protein levels after MLN4924 (1 μM, 24 h) treatment in osteosarcoma cell lines. As shown in Figure 7A-7C, Bmal1 was significantly up-regulated in osteosarcoma cells MG63, Saos-2, and U2OS after MLN4924 treatment. In U2OS osteosarcoma cells, Bmal1 protein levels were induced by MLN4924 in a concentration-dependent manner. (Figure 7D). Nevertheless, MLN4924 did not influence the half-life and ubiquitination of Bmal1 protein (Figure 7E-7G).

Figure 7. MLN4924 increases Bmal1 at the transcriptional level.

Figure 7

Open in a new tab

A-C. The endogenous Bmal1 protein levels detected with Western blot after treatment with MLN4924 (1 μM) or DMSO in MG63 (A), Saos-2 (B) and U2OS (C) cells for 24 h. D. U2OS cells treated with various concentration of MLN4924 for 24 h. Whole cell lysates were analyzed by Western blot using an antibody against Bmal1. The densitometry of Bmal1 treated without MLN4924 was set as 1. Data from various concentration of MLN4924 are presented as fold of this level. E. MLN4924 did not influence the half-life of Bmal1. U2OS cells were transiently transfected with plasmids expressing Bmal1. At 24 h after transfection, MLN4924 (1 μM) or DMSO were added into respective cell culture medium. 24 h later, cells were treated with cycloheximide (CHX) for 0, 3, 6, 9 and 12 h. Equal amounts of whole cell lysates were analyzed by Western blot with a Flag antibody. Actin was used as an internal control. F. The graph illustrates the quantification of Bmal1 by densitometry of triplicate experiments (mean ± SEM). G. MLN4924 did not influence the ubiquitination of Bmal1. Bmal1 and HA-Ub expression plasmids were transiently transfected into U2OS cells. At 24 h after transfection, MLN4924 or DMSO were added into respective cell culture medium. 24 h later, cells were treated with MG132 for 8 h. Equal amounts of whole cell lysates were used for immunoprecipitation (IP). The protein immunoprecipitated by Bmal1 antibody was analyzed by Western blot with HA and Bmal1 antibody. H. MLN4924 increased the Bmal1 transcription. U2OS cells were treated with MLN4924 (1 μM) or DMSO for 24 h, and the total RNA was extracted. The Bmal1 mRNA level was examined with qPCR using specific primers. The expression of Bmal1 in cells treated with DMSO was set as 1. Data from MLN4924-treated cell were presented as fold of this level. Each value is the mean ± SEM of three replicates from a single assay (**P < 0.01 by unpaired t test). I. U2OS cells were synchronized with dexamethasone in the presence of MLN4924 (1 μM) or DMSO, and then harvested every 4 h beginning 24 h after synchronization. The Bmal1 mRNA level was examined with qPCR using specific primers. The expression of Bmal1 in cells treated with DMSO at 36 h was set as 1. Data from other treatments were presented as fold of this level. Each value is the mean ± SEM of three replicates form a single assay. Solid line, DMSO; dashed line, MLN4924.

We therefore examined the effect of MLN4924 on Bmal1 transcription. As shown in Figure 7H, MLN4924 (1 μM) significantly up-regulated the mRNA level of Bmal1. We further examined the effect of MLN4924 on the rhythmic expression of Bmal1. U2OS cells were synchonization with dexamethasone in the presence or absence of MLN4924 (1 μM), and then harvested every 4 h beginning 24 h after synchonization. In the absence of MLN4924, Bmal1 expression showed a circadian rhythm, peaking at 36 h after snchronization. MLN4924 disrupted the circadian rhythm; Bmal1 expression was increased in all time points in the presence of MLN4924 (Figure 7I). It should be noted that both RORα mRNA and protein levels were significantly elevated under synchronized conditions (Supplementary Figure S2).

Bmal1 participates in the MLN4924-induced cell growth inhibition

To determine whether MLN4924 acts through Bmal1 to suppress cell growth, U2OS osteosarcoma cells were transfected with two distinct Bmal1-specific siRNAs (Figure 8A). The cells were treated 48 and 72 h with MLN4924 (3 μM) or DMSO at 48 h after transfection, and the cell proliferation was monitored with an MTT assay. Compared with cells transfected with control siRNA, MLN4924 was significantly less effective in suppressing the growth of Bmal1-depleted cells (cell viability: 48 h, Control: 69.83% ± 3.41, Bmal1-siRNA-1: 84.73% ± 2.56, P = 0.0013, Bmal1-siRNA-2: 86.99% ± 1.21, P < 0.0001; 72 h, Control: 56.37% ± 3.98, Bmal1-siRNA-1: 69.57%± 0.99, P = 0.0028, Bmal1-siRNA-2: 69.50% ± 1.82, P = 0.005, Figure 8B).

Figure 8. Bmal1 participates in the MLN4924-induced cell growth inhibition.

Figure 8

Open in a new tab

A. U2OS osteosarcoma cells were transfected with two distinct Bmal1-specific siRNAs or a negative control siRNA. 72 h after transfection, whole cell lysates were analyzed by Western blot using an antibody against Bmal1. B. U2OS cells were treated with MLN4924 (3 μM) or DMSO at 48 h after transfection with Bmal1-specific siRNAs or negative control siRNA, and the cell proliferation was monitored with an MTT assay at 48 and 72 h after MLN4924 treatment. Each value is the mean ± SEM of three replicates form a single assay. C. U2OS cells were treated with MLN4924 (3 μM) or DMSO at 48 h after transfection with RORα-specific siRNA or/and Bmal1-expressing plasmid, and the cell proliferation was monitored with MTT assay at 48 h after MLN4924 treatment. Each value is the mean ± SEM of three replicates from a single assay. (* compared with control group; # compared with RORα-siRNA-1 group. *P < 0.05, **P< 0.01, ##P< 0.01 by post hoc Bonferroni t test). D. U2OS cells transfected with Bmal1-specific siRNA or negative control siRNA were treated with MLN4924 (1 μM) for 0, 24 and 48 h. Cells were harvested and fixed in ice-cold 70% ethanol overnight at −20°C, then stained with PI (5 μg/100 μL) for 30 min at 4 °C in the dark. DNA profiles were analyzed by flow cytometry. E. The graph illustrates the percentage of > 4N cell of four replicates from a single assay (**P < 0.01 by post hoc Bonferroni t test).

We also overexpressed Bmal1 in U2OS cells, and the anti-proliferative efficacy of MLN4924 was analyzed with MTT assay. As shown in Figure 8C, overexpression of Bmal1 significantly enhanced the effect of MLN4924 in both control and RORα-depleted U2OS cells. (Cell viability: Control: 74.80% ± 1.88, RORα-siRNA: 84.40% ± 3.17, Control+Bmal1: 58.5% ± 1.91, RORα-siRNA+Bmal1: 63.5% ± 2.13).

To further examine whether Bmal1 participates in MLN4924-induced cell cycle distribution, flow cytometry analysis was performed in U2OS cells transfected with control or Bmal1-specific siRNA-1 after MLN4924 (1 μM) treatment for 0, 24 and 48 h. As shown in Figure 8D-8E, Bmal1 depletion significantly attenuated the G2/M cell cycle arrest after 48h treatment, as illustrated with percentage of cells at > 4N stages (24 h, Control: 8.09% ± 3.24, Bmal1-siRNA: 6.12% ± 1.33, P = 0.63; 48 h, Control: 46.89% ± 0.13, Bmal1-siRNA: 26.96% ± 0.75, P = 0.0014).

DISCUSSION

In this study, we have shown that a Nedd8-activating enzyme inhibitor, MLN4924, suppresses proliferation of osteosarcoma cells through G2/M cell cycle arrest and apoptosis. In addition, we have demonstrated that the circadian clock components RORα and Bmal1 play important roles in the MLN4924 effect in osteosarcoma cells. MLN4924 stabilizes a cullin substrate RORα, which in turn transactivates Bmal1. Downregulation of RORα or Bmal1 in U2OS osteosarcoma cells attenuates the MLN4924-induced cell growth suppression as well as G2/M cell cycle arrest.

Physiology and behavior are subjected to daily oscillations driven by an endogenous circadian clock. Disruption of the circadian rhythm may lead to a series of disorders, including cancer. A study that followed 78,562 nurses showed that the nurses who always worked night shift for at least thirty years had a significantly increased risk of breast cancer as compared with those who only worked during daylight [25–27]. Accumulative evidence has shown that Bmal1 and RORα are tumor suppressors. Jiang et al have demonstrated that Bmal1 level is downregulated in pancreatic cancer [21]. Bmal1 is transcriptionally silenced by promoter CpG island hypermethylation in hematologic malignancies, such as diffuse large B-cell lymphoma and acute lymphocytic and myeloid leukemia [28]. Overexpression of Bmal1 inhibits, whereas RNA interference of Bmal1 promotes tumor cell proliferation as well as cell invasion. Mechanistically, overexpression of Bmal1 induces G2/M cell cycle arrest [22, 24]. Baek and colleagues have demonstrated that RORα is downregulated in breast cancer [19]. They also found a reduction of RORα phosphorylation in human colorectal tissues [29]. Moreover, Xu and colleagues have demonstrated that RORα suppresses breast tumor proliferation and invasion [30].

In this study, we have demonstrated that MLN4924 decreases the ubiquitination of RORα and subsequently its degradation in osteosarcoma cells. Although p21 is transcriptionally regulated by RORα, and p21 was indeed upregulated after MLN4924 treatment in U2OS osteosarcoma cells, p21 does not seem to play a significant role in the effect of MLN4924 in U2OS cells. Nevertheless, p21 may play a role in the effect of MLN4924 in MG63 and SaoS-2 osteosarcoma cells, considering that MLN4924 induced apoptosis in MG63 and SaoS-2, but not in U2OS cells.

We have further demonstrated that Bmal1, another transcriptional target of RORα, plays a critical role in MLN4924-induced cell growth suppression. Bmal1 is able to transactivate Wee1, which may in turn inhibit cyclin B/CDK1 to halt cells at G2/M cell cycle [31]. Indeed, MLN4924 significantly upregulated Wee1 and RNAi of RORα led to significant reduction in Wee1 (Supplementary Figure S3).

In summary, this study provides a rationale for clinical trials of MLN4924 in osteosarcoma. Our data indicate an important role of circadian clock in the anti-cancer effect of MLN4924 in osteosarcoma cells. As RORα and Bmal1 oscillate in a circadian manner, it will be intriguing to determine if the effect of MLN4924 is dependent on the circadian rhythm.

MATERIALS AND METHODS

Cell culture

Human osteosarcoma cell lines (U2OS, MG63 and Saos-2) were grown at 37 °C under 5% CO2 in Dulbecco's modified Eagle medium (DMEM) supplemented with 10% fetal bovine serum (FBS) and 100 U/mL of penicillin/streptomycin.

Antibodies and reagents

Antibodies against Bmal1 (sc-8550) and RORα (sc-28612) were obtained from Santa Cruz Biotechnology. Antibodies against Flag tag (M2, A2220) and Wee1 (SAB4503088) were from Sigma. Antibodies against HA tag (C29F4) and p21 (2947S) were from Cell Signaling Technology. MLN4924 was purchased from Med Chem Express. Cycloheximide (CHX), dexamethasone (DEX), Trizol, methylthiazolyldiphenyl-tetrazolium bromide (MTT) and propidium iodide (PI) were purchased from Sigma.

Tumor xenografts in mice

Nude mice at 4-6 weeks of age were purchased from SLAC Animal Center (Shanghai, China). MG63 cells (1 × 106 in 200 μL of PBS) were injected subcutaneously near the scapula of the nude mice. 10 days after injection, the mice were randomly separated into two groups that received MLN4924 (30 mg/kg) or vehicle via intraperitoneal (i.p.) injection (twice a day for 3 days followed by no treatment for 2 days). Mice were euthanized after 15 days of the treatment and tumors were weighted. All animals were housed and handled in accordance with the institutional guide for the care and use of laboratory animals.

RNA interference

The target sequences for the siRNAs against RORα, Bmal1, p21 and negative control (Control) siRNA were as following:

RORα-siRNA-1: 5′- GCCAAACGCAUUGAUGG AUTT -3′;

RORα-siRNA-2: 5′- GGAGUUGUUCACUUCAG AATT -3′;

Bmal1-siRNA-1: 5′- GGCCUUCAGUAAAGGUU GATT -3′;

Bmal1-siRNA-2: 5′- GGUGAAAUCUAUGGAAU AUTT-3′;

p21-siRNA-1: 5′- GAUGGAACUUCGACUUU GUTT-3′;

p21-siRNA-2: 5′-CCUCUGGCAUUAGAAUU AUTT-3′.

Control: 5′- UUCUCCGAACGUGCACGUTT -3′.

All siRNAs were purchased from Gene Pharma (Suzhou, China).

Analysis of protein stability

U2OS cells were transfected with plasmids expressing Bmal1 or Flag-RORα using Lipofectamine 2000 reagent according to the manufacturer's protocol. At 48 h after transfection, cells were incubated with 0.1mg/mL cycloheximide (CHX) to inhibit protein synthesis. Cells were lysed with 2% SDS buffer (2% SDS, 150 mM NaCl, 10 mM Tris–HCl, pH 8.0, PMSF and protease inhibitor cocktail) at 0, 3, 6, 9 and 12 h after CHX treatment. Equal amounts of whole cell lysates were analyzed by Western blot with respective antibodies.

Immunoprecipitation

U2OS cells were transfected with plasmids expressing Bmal1 or Flag-RORα and HA-tagged ubiquitin. After treatment, cells were lysed in 2% SDS buffer and boiled for 10 min followed by sonication. Lysates were diluted 1:10 in dilution buffer (10 mM Tris–HCl, pH 8.0, 150 mM NaCl, 2 mM EDTA, 1% Triton X-100), incubated at 4 °C for 1 h with rotation and centrifuged at 13000 g for 30 min. 500 μg of cell lysates were incubated with 1μg of antibody with constant agitation overnight at 4 °C. Then, 30 μL of protein-A agarose bead slurry was added to pull down the immune-complexes. Immunoprecipitated proteins were washed with washing buffer (10 mM Tris–HCl, pH 8.0, 1 M NaCl, 1 mM EDTA, 1% NP-40). After boiling with 2 × SDS loading buffer, the protein samples were analyzed by Western blot with respective antibodies.

Real-time quantitative PCR (qPCR)

Total RNA was extracted using Trizol reagent according to the manufacturer's instruction. 2 μg of total RNA were reverse-transcribed using the RevertAid First Strand cDNA Synthesis Kit (Fermentas). The mRNA levels were examined with qPCR using 1 × SYBR Green PCR master mix (Fermentas) by C1000 touch Thermal Cycler (Bio-Rad). The primers were as following:

Actin-Forward: 5′-GGCATGGGTCAGAAGGATT-3′;

Actin-Reverse: 5′-TGGTGCCAGATTTTCTCCA-3′;

Bmal1-Forward: 5′-CCAAGAAAGTATGGACACAGACAAA-3′;

Bmal1-Reverse: 5′-GCATTCTTGATCCTTCCTTG GT-3′;

RORα-Forward: 5′-CAGGCTTCTTTCCCTACTGTTCGT-3′;

RORα-Reverse: 5′-CCGCTGCTTGTTTTGATAGTTCTC-3′.

MTT assay

Cells were transfected with siRNAs targeting RORα, Bmal1 or p21, respectively. 24 h after transfection, cells were seeded in 96 well plates at the density of 1 × 103 cells per well and incubated with MLN4924 (3 μM). After various times, the cells were stained with 20 μL of sterile MTT dye (5 mg/mL) for 4 h at 37 °C followed by removal of the culture medium and the addition of 200 μL of DMSO. The absorbance at 570 nm was measured and the absorbance at 630 nm was used as a reference. All assays were conducted at least three times and performed in triplicate on different days using different batches of cells.

Flow cytometry

After treatment, cells were harvested and washed with cold PBS and fixed in ice-cold 70% ethanol overnight at −20°C, The fixed cells were incubated with 100 μL of propidium iodide (PI, 50 μg/mL) for 30 min at 4 °C in the dark. At least 10,000 cells were analyzed of the cell cycle using a Cytomics FC 500 instrument (Beckman Coulter) equipped with CXP software. To analyze apoptosis, cells were stained with Annexin V-FITC/PI, and apoptotic cells were examined by flow cytometry.

Statistical analysis

All statistical analyses were performed using the Prism 6.01 (Graph Pad Software, San Diego, CA). Statistically significant differences between groups were determined by a repeated ANOVA followed by unpaired t test.

SUPPLEMENTARY MATERIALS FIGURES

Footnotes

CONFLICTS OF INTEREST

No potential conflicts of interest were disclosed.

GRANT SUPPORT

This work was supported by the National Basic Research Program of China (2012CB517904), the National Natural Science Foundation of China (31371187), the Lotus Scholar Professorship Funds from Hunan Province Government and a research grant provided by the Central South University of China (2014zzts064).

REFERENCES

  • 1.Isakoff MS, Bielack SS, Meltzer P, Gorlick R. Osteosarcoma: Current Treatment and a Collaborative Pathway to Success. J Clin Oncol. 2015;33:3029–3035. doi: 10.1200/JCO.2014.59.4895. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Tang QL, Xie XB, Wang J, Chen Q, Han AJ, Zou CY, Yin JQ, Liu DW, Liang Y, Zhao ZQ, Yong BC, Zhang RH, Feng QS, et al. Glycogen synthase kinase-3beta NF-kappaB signaling and tumorigenesis of human osteosarcoma. J Natl Cancer Inst. 2012;104:749–763. doi: 10.1093/jnci/djs210. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Liu HC, Enikolopov G, Chen Y. Cul4B regulates neural progenitor cell growth. BMC Neurosci. 2012;13:112. doi: 10.1186/1471-2202-13-112. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Shah JJ, Jakubowiak AJ, O'Connor OA, Orlowski RZ, Harvey RD, Smith MR, Lebovic D, Diefenbach C, Kelly K, Hua Z, Berger AJ, Mulligan G, Faessel HM, Tirrell S, Dezube BJ, Lonial S. Phase I Study of the Novel Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (MLN4924) in Patients with Relapsed/Refractory Multiple Myeloma or Lymphoma. Clin Cancer Res. 2016;22:34–43. doi: 10.1158/1078-0432.CCR-15-1237. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Soucy TA, Smith PG, Milhollen MA, Berger AJ, Gavin JM, Adhikari S, Brownell JE, Burke KE, Cardin DP, Critchley S, Cullis CA, Doucette A, Garnsey JJ, et al. An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer. Nature. 2009;458:732–736. doi: 10.1038/nature07884. [DOI] [PubMed] [Google Scholar]
  • 6.Nawrocki ST, Griffin P, Kelly KR, Carew JS. MLN4924: a novel first-in-class inhibitor of NEDD8-activating enzyme for cancer therapy. Expert Opin Investig Drugs. 2012;21:1563–1573. doi: 10.1517/13543784.2012.707192. [DOI] [PubMed] [Google Scholar]
  • 7.Khalife J, Radomska HS, Santhanam R, Huang X, Neviani P, Saultz J, Wang H, Wu YZ, Alachkar H, Anghelina M, Dorrance A, Curfman J, Bloomfield CD, et al. Pharmacological targeting of miR-155 via the NEDD8-activating enzyme inhibitor MLN4924 (Pevonedistat) in FLT3-ITD acute myeloid leukemia. Leukemia. 2015;29:1981–1992. doi: 10.1038/leu.2015.106. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Visconte V, Nawrocki ST, Espitia CM, Kelly KR, Possemato A, Beausoleil SA, Han Y, Carraway HE, Nazha A, Advani AS, Maciejewski JP, Sekeres MA, Carew JS. Comprehensive quantitative proteomic profiling of the pharmacodynamic changes induced by MLN4924 in acute myeloid leukemia cells establishes rationale for its combination with azacitidine. Leukemia. 2015 doi: 10.1038/leu.2015.250. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Chen P, Hu T, Liang Y, Jiang Y, Pan Y, Li C, Zhang P, Wei D, Li P, Jeong LS, Chu Y, Qi H, Yang M, Hoffman RM, Dong Z, Jia L. Synergistic inhibition of autophagy and neddylation pathways as a novel therapeutic approach for targeting liver cancer. Oncotarget. 2015;6:9002–9017. doi: 10.18632/oncotarget.3282. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Kuo KL, Ho IL, Shi CS, Wu JT, Lin WC, Tsai YC, Chang HC, Chou CT, Hsu CH, Hsieh JT, Chang SC, Pu YS, Huang KH. MLN4924 a novel protein neddylation inhibitor suppresses proliferation and migration of human urothelial carcinoma: In vitro and in vivo studies. Cancer Lett. 2015;363:127–136. doi: 10.1016/j.canlet.2015.01.015. [DOI] [PubMed] [Google Scholar]
  • 11.Ho IL, Kuo KL, Liu SH, Chang HC, Hsieh JT, Wu JT, Chiang CK, Lin WC, Tsai YC, Chou CT, Hsu CH, Pu YS, Shi CS, Huang KH. MLN4924 Synergistically Enhances Cisplatin-induced Cytotoxicity via JNK and Bcl-xL Pathways in Human Urothelial Carcinoma. Sci Rep. 2015;5:16948. doi: 10.1038/srep16948. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Nawrocki ST, Kelly KR, Smith PG, Espitia CM, Possemato A, Beausoleil SA, Milhollen M, Blakemore S, Thomas M, Berger A, Carew JS. Disrupting protein NEDDylation with MLN4924 is a novel strategy to target cisplatin resistance in ovarian cancer. Clin Cancer Res. 2013;19:3577–3590. doi: 10.1158/1078-0432.CCR-12-3212. [DOI] [PubMed] [Google Scholar]
  • 13.Pan WW, Zhou JJ, Yu C, Xu Y, Guo LJ, Zhang HY, Zhou D, Song FZ, Fan HY. Ubiquitin E3 ligase CRL4(CDT2/DCAF2) as a potential chemotherapeutic target for ovarian surface epithelial cancer. J Biol Chem. 2013;288:29680–29691. doi: 10.1074/jbc.M113.495069. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Jia L, Li H, Sun Y. Induction of p21-dependent senescence by an NAE inhibitor MLN4924 as a mechanism of growth suppression. Neoplasia. 2011;13:561–569. doi: 10.1593/neo.11420. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Gu Y, Kaufman JL, Bernal L, Torre C, Matulis SM, Harvey RD, Chen J, Sun SY, Boise LH, Lonial S. MLN4924 an NAE inhibitor suppresses AKT and mTOR signaling via upregulation of REDD1 in human myeloma cells. Blood. 2014;123:3269–3276. doi: 10.1182/blood-2013-08-521914. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Lin JJ, Milhollen MA, Smith PG, Narayanan U, Dutta A. NEDD8-targeting drug MLN4924 elicits DNA rereplication by stabilizing Cdt1 in S phase triggering checkpoint activation apoptosis and senescence in cancer cells. Cancer Res. 2010;70:10310–10320. doi: 10.1158/0008-5472.CAN-10-2062. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Bailly A, Perrin A, Bou Malhab LJ, Pion E, Larance M, Nagala M, Smith P, O'Donohue MF, Gleizes PE, Zomerdijk J, Lamond AI, Xirodimas DP. The NEDD8 inhibitor MLN4924 increases the size of the nucleolus and activates p53 through the ribosomal-Mdm2 pathway. Oncogene. 2016;35:415–426. doi: 10.1038/onc.2015.104. [DOI] [PubMed] [Google Scholar]
  • 18.Kojetin DJ, Burris TP. REV-ERB and ROR nuclear receptors as drug targets. Nat Rev Drug Discov. 2014;13:197–216. doi: 10.1038/nrd4100. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Lee JM, Lee JS, Kim H, Kim K, Park H, Kim JY, Lee SH, Kim IS, Kim J, Lee M, Chung CH, Seo SB, Yoon JB, et al. EZH2 generates a methyl degron that is recognized by the DCAF1/DDB1/CUL4 E3 ubiquitin ligase complex. Mol Cell. 2012;48:572–586. doi: 10.1016/j.molcel.2012.09.004. [DOI] [PubMed] [Google Scholar]
  • 20.Kim H, Lee JM, Lee G, Bhin J, Oh SK, Kim K, Pyo KE, Lee JS, Yim HY, Kim KI, Hwang D, Chung J, Baek SH. DNA damage-induced RORalpha is crucial for p53 stabilization and increased apoptosis. Mol Cell. 2011;44:797–810. doi: 10.1016/j.molcel.2011.09.023. [DOI] [PubMed] [Google Scholar]
  • 21.Jiang W, Zhao S, Jiang X, Zhang E, Hu G, Hu B, Zheng P, Xiao J, Lu Z, Lu Y, Ni J, Chen C, Wang X, Yang L, Wan R. The circadian clock gene Bmal1 acts as a potential anti-oncogene in pancreatic cancer by activating the p53 tumor suppressor pathway. Cancer Lett. 2016;371:314–325. doi: 10.1016/j.canlet.2015.12.002. [DOI] [PubMed] [Google Scholar]
  • 22.Jung CH, Kim EM, Park JK, Hwang SG, Moon SK, Kim WJ, Um HD. Bmal1 suppresses cancer cell invasion by blocking the phosphoinositide 3-kinase-Akt-MMP-2 signaling pathway. Oncol Rep. 2013;29:2109–2113. doi: 10.3892/or.2013.2381. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Khapre RV, Kondratova AA, Susova O, Kondratov RV. Circadian clock protein BMAL1 regulates cellular senescence in vivo. Cell Cycle. 2011;10:4162–4169. doi: 10.4161/cc.10.23.18381. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Zeng ZL, Luo HY, Yang J, Wu WJ, Chen DL, Huang P, Xu RH. Overexpression of the circadian clock gene Bmal1 increases sensitivity to oxaliplatin in colorectal cancer. Clin Cancer Res. 2014;20:1042–1052. doi: 10.1158/1078-0432.CCR-13-0171. [DOI] [PubMed] [Google Scholar]
  • 25.Hansen J. Risk of breast cancer after night- and shift work: current evidence and ongoing studies in Denmark. Cancer Causes Control. 2006;17:531–537. doi: 10.1007/s10552-005-9006-5. [DOI] [PubMed] [Google Scholar]
  • 26.Kolstad HA. Nightshift work and risk of breast cancer and other cancers--a critical review of the epidemiologic evidence. Scand J Work Environ Health. 2008;34:5–22. doi: 10.5271/sjweh.1194. [DOI] [PubMed] [Google Scholar]
  • 27.Lee S, Donehower LA, Herron AJ, Moore DD, Fu L. Disrupting circadian homeostasis of sympathetic signaling promotes tumor development in mice. PLoS One. 2010;5:e10995. doi: 10.1371/journal.pone.0010995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Taniguchi H, Fernandez AF, Setien F, Ropero S, Ballestar E, Villanueva A, Yamamoto H, Imai K, Shinomura Y, Esteller M. Epigenetic inactivation of the circadian clock gene BMAL1 in hematologic malignancies. Cancer Res. 2009;69:8447–8454. doi: 10.1158/0008-5472.CAN-09-0551. [DOI] [PubMed] [Google Scholar]
  • 29.Lee JM, Kim IS, Kim H, Lee JS, Kim K, Yim HY, Jeong J, Kim JH, Kim JY, Lee H, Seo SB, Kim H, Rosenfeld MG, Kim KI, Baek SH. RORalpha attenuates Wnt/beta-catenin signaling by PKCalpha-dependent phosphorylation in colon cancer. Mol Cell. 2010;37:183–195. doi: 10.1016/j.molcel.2009.12.022. [DOI] [PubMed] [Google Scholar]
  • 30.Xiong G, Wang C, Evers BM, Zhou BP, Xu R. RORalpha suppresses breast tumor invasion by inducing SEMA3F expression. Cancer Res. 2012;72:1728–1739. doi: 10.1158/0008-5472.CAN-11-2762. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Visconti R, Della Monica R, Palazzo L, D'Alessio F, Raia M, Improta S, Villa MR, Del Vecchio L, Grieco D. The Fcp1-Wee1-Cdk1 axis affects spindle assembly checkpoint robustness and sensitivity to antimicrotubule cancer drugs. Cell Death Differ. 2015;22:1551–1560. doi: 10.1038/cdd.2015.13. [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

oncotarget-07-66087-s001.pdf (1.4MB, pdf)

Articles from Oncotarget are provided here courtesy of Impact Journals, LLC

RESOURCES